Press "Enter" to skip to content

Theralase Technologies has a 256 per cent upside, says Mackie Research – Cantech Letter

admin 0

Theralase Technologies has a 256 per cent upside, says Mackie Research  Cantech Letter

Analyst André Uddin of Mackie Research says Theralase Technologies is targeting a significant market opportunity and an unmet medical need.

“bladder cancer” – Google News

(Visited 4 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *